3063042-21-4
Chemical Structure
Ferroptosis inducer-16
Synonym(s): anti-NSCLC agent-2
- CAS No.: 3063042-21-4
- Formula:C27H20Cl2N2O8S
- Molecular Weight:603.43
InChIKey: NIAOWYAOZYDFOM-UHFFFAOYSA-N
SMILES: O=S(C1=[N+]([O-])ON=C1OCCOC2=CC(O3)=C(C=C2)C(C)=C(CC4=CC(Cl)=CC(Cl)=C4)C3=O)(C5=CC=CC=C5)=O
Biological Activity: Ferroptosis inducer-16 (anti-NSCLC agent-2) is a nitric oxide (NO) donor and a ferroptosis inducer. Ferroptosis inducer-16 inhibits DNA synthesis and colony formation. Ferroptosis inducer-16 disrupts lysosomal integrity by releasing NO, triggers iron overload and oxidative stress, downregulates the SLC7A11-GPX4 axis, depletes GSH, and accumulates lipid peroxides. Ferroptosis inducer-16 inhibits tumor growth in an OVCAR8/ADR xenograft mouse model without obvious toxicity, and can be used in the study of non-small cell lung cancer and drug-resistant ovarian cancer[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Ferroptosis inducer-16 | Ferroptosis inducer-16 (anti-NSCLC agent-2) is a nitric oxide (NO) donor and a ferroptosis inducer. Ferroptosis inducer-16 inhibits DNA synthesis and colony formation. Ferroptosis inducer-16 disrupts lysosomal integrity by releasing NO, triggers iron overload and oxidative stress, downregulates the SLC7A11-GPX4 axis, depletes GSH, and accumulates lipid peroxides. Ferroptosis inducer-16 inhibits tumor growth in an OVCAR8/ADR xenograft mouse model without obvious toxicity, and can be used in the study of non-small cell lung cancer and drug-resistant ovarian cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Wang W, et al. Novel Hybrids of 3-Substituted Coumarin and Phenylsulfonylfuroxan as Potent Antitumor Agents against Wild-Type and Drug-Resistant Nonsmall Cell Lung Cancer Cell Lines. J Med Chem. 2026;69(6):7238-7261. [Content Brief]
- [2]. Weng J, et al. A Novel Nitric Oxide Donor Induced Ferroptosis in Drug-Resistant Ovarian Cancer Cells through Lysosomal Iron Metabolism Regulation and Lipid Peroxidation. ACS Pharmacol Transl Sci. 2026 Jun 3;9(6):1519-1530. [Content Brief]
Keywords
